Does Follicle-Stimulating Hormone (FSH) increase the success of Intrauterine Insemination (IUI) cycles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does FSH Increase the Success of IUI Cycles?

Yes, FSH-based ovarian stimulation significantly increases IUI success rates compared to natural cycles or clomiphene citrate, and should be the standard approach for couples with unexplained infertility and adequate sperm parameters (TMSC >10 million). 1

Primary Recommendation for Ovarian Stimulation

In couples with unexplained infertility and men with a total motile sperm count (TMSC) above 10 million, IUI should be combined with ovarian stimulation to improve live birth rates. 1 This represents moderate-strength evidence from comprehensive international guidelines.

FSH vs. Clomiphene Citrate: The Evidence

The superiority of FSH over clomiphene citrate is well-established, though the magnitude of benefit must be weighed against costs and multiple pregnancy risks:

  • Gonadotropins (FSH) yield significantly higher pregnancy rates than clomiphene citrate (OR = 1.8,95% CI 1.2–2.7), though clomiphene remains an acceptable alternative when cost is a primary concern. 1

  • A 2018 randomized controlled trial comparing FSH to clomiphene citrate found ongoing pregnancy rates of 31% with FSH versus 26% with clomiphene citrate, though this difference did not reach statistical significance (RR = 1.16,95% CI: 0.93-1.47). 2 Importantly, both groups had similarly low multiple pregnancy rates (1.4% vs 2.2%) when strict cancellation criteria were applied.

  • An earlier RCT demonstrated pregnancy rates per cycle of 13% with FSH versus 4% with clomiphene citrate (P = 0.02), with all pregnancies being singleton. 3

  • Clomiphene citrate or tamoxifen are acceptable alternatives to low-dose gonadotropins for lower multiple pregnancy rates and reduced costs, although at a lower live birth rate than with gonadotropins. 1

Optimal FSH Dosing Protocol

When gonadotropins are used in IUI, regimens with 75 IU or lower should be used because higher doses have similar pregnancy rates but increase multiple pregnancy rates. 1, 4

The evidence supports a conservative approach:

  • Low-dose FSH (75 IU/day starting dose) is recommended as the standard protocol. 4, 5

  • A late low-dose technique (75 IU/day from cycle day 7 until the leading follicle reaches >17 mm) has proven efficacious, safe, and economical, with pregnancy rates of 13% per cycle and no cases of ovarian hyperstimulation syndrome. 3

  • Recent data suggests that FSH dosing based on age and ovarian reserve markers (using nomograms) may optimize outcomes and cost-effectiveness, though this approach requires validation in clinical practice. 6

Critical Safety Parameters

To prevent high rates of multiple gestation pregnancies in IUI with ovarian stimulation, IUI should be withheld when more than two dominant follicles >15 mm or more than five follicles >10 mm at the time of hCG injection or LH surge are present. 1, 4, 5

This strict cancellation criterion is essential because:

  • Multiple pregnancy risk is 10-20% with gonadotropin stimulation without proper cycle management. 5

  • The goal is to achieve exactly 2 mature follicles (>15mm) to balance success against multiple pregnancy risk. 4

  • Compared to one dominant follicle, pregnancy rates increase by 5%, 8%, and 8% with two, three, or four dominant follicles, respectively, but multiple pregnancy risk increases to 6%, 14%, and 10% respectively. 1

Cost-Effectiveness Considerations

In couples with unexplained infertility and men with a TMSC of >10 million and a prognosis of pregnancy without assistance <30% within a year, at least three cycles of IUI with ovarian stimulation is the most cost-effective option. 1

The economic analysis demonstrates:

  • IUI with ovarian stimulation is more cost-effective than proceeding directly to IVF, particularly when strict cancellation criteria minimize multiple pregnancies. 1

  • At least 3 consecutive IUI cycles should be performed before transitioning to IVF/ICSI, as cycle fecundity remains acceptable through cycle 3. 4, 5

  • When IVF with elective single embryo transfer achieves ongoing pregnancy rates exceeding 38%, it becomes preferable to IUI with ovarian stimulation. 1

Common Pitfalls to Avoid

  • Do not add GnRH agonists to gonadotropins as they increase multiple pregnancy rates and costs without improving pregnancy rates. 1, 5

  • Do not use FSH doses higher than 75 IU/day as a starting dose, as higher doses yield similar pregnancy rates but significantly increase multiple pregnancy risk. 1

  • Do not proceed with insemination when >2 follicles >15mm develop, as this dramatically increases high-order multiple pregnancy risk without proportional benefit. 4, 5

  • In women with polycystic ovary syndrome and high AMH levels, standard nomogram-based FSH dosing may not be adequate and requires clinical adjustment. 6

Special Populations

For younger women (<35 years) with elevated basal FSH levels (≥10 U/L), gonadotropin-stimulated IUI remains a viable option with comparable pregnancy outcomes to those with normal FSH, though they require longer stimulation periods and face higher cycle cancellation rates. 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.